Pantoprazole Cadila Pharmaceuticals (Europe)

Pantoprazole, the active ingredient in Pantoprazole Cadila (Europe), is a proton pump inhibitor presented as a tablet for oral use. It reduces gastric acid secretion and is used to treat acid‑related gastrointestinal disorders in adults and children. GNH USA supplies Pantoprazole Cadila (Europe) as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazole is a proton pump inhibitor that acts on the gastric parietal cell H+/K+ ATPase to lower stomach acidity. - Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief of heartburn and promotes healing of erosive esophagitis. - Peptic ulcer disease: facilitates ulcer healing and reduces recurrence risk. - Zollinger‑Ellison syndrome: controls hyper‑secretion of gastric acid in this rare endocrine disorder. - NSAID‑induced ulcer prophylaxis: lowers the incidence of ulcer formation in patients receiving chronic non‑steroidal anti‑inflammatory therapy.

Pantoprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Diarrhoea: loose stools that may resolve with continued therapy. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach area. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reactions (e.g., anaphylaxis, angioedema). - Clostridioides difficile‑associated diarrhoea. - Hepatic enzyme elevation or hepatitis. - Hypomagnesemia with prolonged use. - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Bone fractures with long‑term high‑dose therapy.

Before initiating therapy, consider the following precautions. - Assess renal function: dose adjustment may be needed in severe impairment. - Monitor magnesium levels: prolonged use can cause hypomagnesemia. - Use with caution in hepatic impairment: metabolism occurs in the liver. - Avoid in patients with known hypersensitivity to pantoprazole or other PPIs. - Review concomitant medications for potential interactions. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Pantoprazole may interact with several medicines; monitoring is advised.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk. - Atazanavir: decreased absorption, leading to sub‑therapeutic antiviral levels. - High‑dose methotrexate: increased toxicity due to reduced renal clearance.

Moderate Interactions (Monitor Closely): - Warfarin: variable INR, require more frequent coagulation monitoring. - Digoxin: possible increase in serum concentration. - Diazepam: may experience elevated plasma levels, watch for enhanced sedation.